Logo

NTHI

NEONC TECHNOLOGIES HOLDINGS, INC.

NTHI

NEONC TECHNOLOGIES HOLDINGS, INC. • NASDAQ
$8.95 ▲ 4.37% (+0.38)
Market Cap $174.30 M
52w High $25.00
52w Low $3.20
Dividend Yield 0%
P/E -3.57
Volume 39.02K
Outstanding Shares 19.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $6.935M ▲ $-8.616M ▼ 0% $-0.45 ▼ $-7.636M ▼
Q2-2025 $0 ▼ $5.708M ▼ $-5.68M ▲ 0% ▲ $-0.3 ▲ $-5.708M ▲
Q1-2025 $39.99K ▲ $37.617M ▲ $-38.002M ▼ -95.029K% ▼ $-2.1 ▼ $-37.693M ▼
Q4-2024 $20K ▲ $2.134M ▼ $-2.253M ▼ -11.265K% ▼ $-0.12 ▼ $-2.188M ▼
Q3-2024 $0 $2.172M $-2.184M 0% $-0.097 $-2.184M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.513M ▲ $4.083M ▲ $15.897M ▲ $-11.814M ▲
Q2-2025 $125.039K ▼ $2.988M ▼ $14.804M ▼ $-11.815M ▼
Q1-2025 $5.439M ▲ $8.442M ▲ $18.065M ▲ $-9.624M ▼
Q4-2024 $64.893K ▼ $3.417M ▲ $8.922M ▲ $-5.505M ▼
Q3-2024 $1.335M $2.744M $8.011M $-5.267M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.616M ▼ $-5.809M ▼ $0 $7.197M ▲ $1.388M ▲ $-5.809M ▼
Q2-2025 $-4.199K ▲ $-5.314M ▲ $0 $0 ▼ $-5.314M ▼ $-5.314M ▲
Q1-2025 $-38.002M ▼ $-5.65M ▼ $0 $11.024M ▲ $5.374M ▲ $-5.65M ▼
Q4-2024 $-2.253M ▼ $-954.404K ▲ $0 $-315.33K ▼ $-1.27M ▼ $-954.404K ▲
Q3-2024 $-2.184M $-3.087M $0 $2.889M $-197.907K $-3.087M

Five-Year Company Overview

Income Statement

Income Statement NTHI is a pure development‑stage biotech with no product revenue so far. The income statement mainly reflects research, development, and corporate expenses, leading to small but persistent losses each year. Earnings per share have been negative and somewhat volatile, which is typical for a company that is funding clinical trials without any commercial products yet. Profitability will depend entirely on whether one or more drug candidates successfully reach the market in the future.

Balance Sheet

Balance Sheet The reported balance sheet is very thin and mostly symbolic in the data shown, with negligible assets and a small negative equity position. That suggests the company has accumulated losses and relies heavily on external capital rather than internally generated funds. Formal debt levels appear minimal, which reduces balance sheet leverage risk but increases dependence on future equity raises, partnerships, or milestone payments to finance operations and trials.

Cash Flow

Cash Flow There is no meaningful historical cash flow data shown, but the profile is typical of an early‑stage biotech: cash is mainly consumed by research, clinical development, and overhead, with no operating inflows from sales. Future cash flow will likely be driven by financing events (equity issues, partnerships, or grants) until the company can secure approvals and begin generating product revenue, which may still be several years away given current trial stages.

Competitive Edge

Competitive Edge NTHI’s competitive position rests on a focused specialty: delivering cancer drugs across the blood‑brain barrier for brain tumors and other central nervous system diseases. The company holds a large and long‑dated global patent portfolio around its NEO platform and key drug candidates, which can act as a strong intellectual property moat. Its non‑invasive intranasal delivery approach, and attempts to improve existing brain cancer therapies, give it a differentiated story in a field with high unmet need. However, it operates in a crowded and high‑stakes oncology space, where it must compete against both small biotechs and large pharmaceutical companies with deeper resources.

Innovation and R&D

Innovation and R&D Innovation is the core of NTHI’s value. The NEO platform is designed to bypass or open the blood‑brain barrier, with lead candidates NEO100 and NEO212 already in clinical development and additional assets such as NEO214 and NEO400 in earlier stages. The company is exploring both brain cancers and broader applications like multiple myeloma and skin damage, plus a pediatric brain tumor program that could access special regulatory pathways. Its strategy is research‑heavy and clinically ambitious, but success depends on positive trial results, regulatory approvals, and the ability to translate promising early data into robust, larger‑scale outcomes.

Summary

NTHI is a very early‑stage, clinical‑focused biotech with no current revenue and a financial profile dominated by research spending and small ongoing losses. Its balance sheet appears light and will likely need continued outside funding to sustain development. The main source of potential value is its brain‑targeted drug delivery platform and sizeable patent estate, which together create a clear but still unproven competitive position in neuro‑oncology and related areas. The outlook is highly dependent on clinical trial milestones, regulatory decisions, and future financing or partnerships, making the company’s trajectory more about scientific and execution risk than about current financial performance.

NEWS

November 13, 2025 · 9:00 AM UTC

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

Read more

November 7, 2025 · 9:00 AM UTC

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

Read more

October 9, 2025 · 9:00 AM UTC

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Read more

September 29, 2025 · 9:00 AM UTC

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Read more

September 10, 2025 · 9:40 AM UTC

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

Read more